CONVATEC GROUP PLC ORD GBP0.1
Symbol: CTEC
Streaming is not available when market closed. Some prices may be as at close of business from the previous working day.
Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.
Invest in this share within an ISA, JISA, SIPP or Investment Account
Charts
Company
Business Summary
Convatec Group Plc is a United Kingdom-based medical products and technologies company. The Company is engaged in the development, manufacture and sale of medical products, services, and technologies. It is focused on solutions for the management of chronic conditions. It markets and sells its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Its Advanced Wound Care includes advanced solutions for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Ostomy Care includes devices, accessories and personalized services for individuals with a stoma. Its Continence and Critical Care includes products and services for people with urinary continence issues, and other devices for critical care. Its Infusion Care includes disposable infusion sets used in insulin pump therapy for people with diabetes.
Financial Summary
BRIEF: For the fiscal year ended 31 December 2023, ConvaTec Group PLC revenues increased 3% to $2.14B. Net income increased from $62.9M to $130.3M. Revenues reflect Ostomy Care segment increase of 17% to $608.3M, Advanced Wound Care segment increase of 12% to $695.3M, U.S segment increase of 10% to $821.5M, Other segment increase of 1% to $828.7M.
Financials
Income Statement - All values are in GBP (M).
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
---|---|---|---|---|---|---|
Total Revenue | 2,142.40 | 2,072.50 | 2,038.30 | 1,894.30 | 1,827.20 | 1,832.10 |
Gross profit | 3,411.60 | 1,126.50 | 1,129.50 | 1,038.30 | 972.70 | 996.60 |
Operating Profit/Loss | 266.60 | 163.60 | 204.10 | 227.50 | 96.90 | 269.40 |
Profit Before Tax | 167.40 | 81.90 | 151.30 | 174.70 | 18.90 | 201.20 |
Profit After Tax | 130.30 | 62.90 | 117.60 | 112.50 | 9.80 | 186.60 |
Equity Holders of Parent Company | 130.30 | 62.90 | 117.60 | 112.50 | 9.80 | 221.60 |
Minority Interest | NIL | NIL | NIL | NIL | NIL | NIL |
Balance Sheet - All values are in GBP (M).
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
---|---|---|---|---|---|---|
Total Non-Current Assets | 2,843.70 | 2,702.70 | 2,563.20 | 2,588.00 | 2,641.50 | 2,757.20 |
Total Current Assets | 870.00 | 889.30 | 1,110.80 | 1,178.50 | 968.30 | 903.20 |
Total Assets | 3,713.70 | 3,592.00 | 3,674.00 | 3,766.50 | 3,609.80 | 3,660.40 |
Total Liabilities | 2,021.00 | 1,982.30 | 1,979.20 | 2,095.80 | 2,048.80 | 2,043.20 |
Total Net Assets | 1,692.70 | 1,609.70 | 1,694.80 | 1,670.70 | 1,561.00 | 1,617.20 |
Shareholders Funds | 1,692.70 | 1,609.70 | 1,694.80 | 1,670.70 | 1,561.00 | 1,617.20 |
Minority Interests | NIL | NIL | NIL | NIL | NIL | NIL |
Total Equity | 1,692.70 | 1,609.70 | 1,694.80 | 1,670.70 | 1,561.00 | 1,617.20 |
Outlook
Broker View
Data shown is based on the past 75 days of broker views.
ActionBrokers |
Strong Buy6 |
Buy9 |
Neutral4 |
Sell0 |
Strong Sell0 |
---|---|---|---|---|---|
Brokers | 6 | 9 | 4 | 0 | 0 |
Consensus |
ConsensusBuy |
Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.
Forecasts
Year | 2024 | 2025 | 2026 |
---|---|---|---|
Revenue | £2,268.22mn | £2,406.75mn | £2,557.47mn |
Pre-tax-Profit | £457.03mn | £521.60mn | £577.93mn |
EPS | £0.12p | £0.14p | £0.16p |
EPS Growth | 13.10% | 16.01% | 14.68% |
P/E | 23.59 | 20.35 | 17.62 |
PEG Ratio | 1.80 | 1.27 | 1.20 |
Dividend | 5.29p | 5.59p | 6.21p |
Yield | 0.00% | 0.00% | 0.00% |
Upgrades & Downgrades (Latest)
Date | Broker | Recommendation | Price | Old Target | New Target | Change |
---|---|---|---|---|---|---|
7th Mar 2024 | JP Morgan Cazenove | Reiteration | 276p | 300p | 323p | Overweight |
6th Mar 2024 | Berenberg Bank | Reiteration | 268p | 290p | 310p | Buy |
15th Nov 2023 | Jefferies | Reiteration | 225p | 0p | 300p | Buy |
15th Nov 2023 | Berenberg Bank | Reiteration | 225p | 0p | 290p | Buy |
7th Sep 2023 | RBC Capital Markets | Upgrade | 231p | 215p | 300p | Outperform |
6th Sep 2023 | Barclays | Reiteration | 231p | 0p | 310p | Overweight |
5th Sep 2023 | Goldman Sachs | Restart Coverage | 229p | 0p | 300p | Buy |
27th Jun 2023 | JP Morgan Cazenove | Reiteration | 207p | 0p | 290p | Overweight |
8th Jun 2023 | JP Morgan Cazenove | Reiteration | 203p | 305p | 290p | Overweight |
19th May 2023 | Barclays | Reiteration | 226p | 295p | 300p | Overweight |
Time & Sales
All prices are in GBX and times are in GMT. Last 20 trades shown. Trade type is estimated and should be treated as indicative only.
Date | Time | Price | Volume | Type |
---|---|---|---|---|
18 Apr 2024 | 17:29 | 282.02 | 21,762 | Sell |
18 Apr 2024 | 17:26 | 283.54 | 12,760 | Buy |
18 Apr 2024 | 17:25 | 283.377 | 1,301 | Buy |
18 Apr 2024 | 17:23 | 283.6 | 48,236 | Buy |
18 Apr 2024 | 17:22 | 283.54 | 1,511 | Buy |
18 Apr 2024 | 17:22 | 283.54 | 22,466 | Buy |
18 Apr 2024 | 17:21 | 281.41 | 1,223 | Sell |
18 Apr 2024 | 17:20 | 282.737 | 16,367 | Sell |
18 Apr 2024 | 17:13 | 281.275 | 92,375 | Sell |
18 Apr 2024 | 17:13 | 283.6 | 30,853 | Buy |
Selected data supplied by Thomson Reuters © View restrictions.